

Figure 1A




Figure 1B




Figure 1C






Figure 1D




Figure 1E

	CCH-OS-D	CCH-OS-O	MG 63.2	LM7	U2OS	SjSA-1	hFOB	H1299
--	----------	----------	---------	-----	------	--------	------	-------

Densitometry ratio	2.85	1.33	3.82	1.49	0.25	1.16	1.67	1.00
--------------------	------	------	------	------	------	------	------	------




Figure 1F

	CCH-OS-D	CCH-OS-O	MG 63.2	LM7	U2OS	SJSA-1	hFOB	H1299
Densitometry ratio	0.15	0.69	0.58	0.39	0.20	0.34	1	0.16





Figure 4A




Figure 4B




Figure 4C, D, E




Figure 4C, D, E Increased p21, p27 but not cyclin D3 in CCH-OSD after Pramlintide treatment

Figure 4C, D, E

D




Figure 4C, D, E Increased p21, p27 but not cyclin D3 in CCH-OSD after Pramlintide treatment

Figure 4C, D, E




Figure 4C, D, E Increased p21, p27 but not cyclin D3 in CCH-OSD after Pramlintide treatment